Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plaquenil for endothelial dysfunction in arterial antiphospholipid syndrome
2015-002182-38Phase 3Terminated
- Sponsor
- Rouen University Hospital
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of hydroxychloroquine in antiphospholipid syndrome (APS) (2 arms), sponsored by Rouen University Hospital. Primary endpoint: Change in endothelium-dependent brachial artery dilation at 6 months. Started Aug 2015; status: terminated.
02
Drugs
hydroxychloroquine
03
Conditions
antiphospholipid syndrome (APS)
Beyond the preview
Go deeper on 2015-002182-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002182-38.